PHARMACY

21st Century Cures legislation is gaining momentum

BY DSN STAFF

 
 
WASHINGTON – The 21st Century Cures legislation spearheaded by Reps. Fred Upton, R-Mich., and Diana DeGette, D-Colo., is gaining momentum in the House Energy and Commerce Committee.
 
“We in Congress are going to take a comprehensive look at what steps we can take to accelerate the pace of cures in America,” the congressional leaders stated in first announcing the initiative. “We are looking at the full arc of this process — from the discovery of clues in basic science, to streamlining the drug and device development process, to unleashing the power of digital medicine and social media at the treatment delivery phase.”
 
Upton, chairman of the Energy and Commerce Committee, has said he wants legislation aimed at accelerating cures and treatments for diseases on the president’s desk by the end of this year.
 
“Over the past two weeks, the 21st Century Cures initiative has moved through the Energy and Commerce Health Subcommittee and full committee, enjoying momentum from a continued flood of support,” the Committee noted on its web page on Friday.  “For more than a year, committee members have brought patients, innovators, caregivers, regulators, researchers, and other thought leaders to the table for an open and collaborative conversation. Their common goal: building a 21st Century health care system that embraces personalized medicine and advances in technology, encourages greater innovation, supports more research, and streamlines the system so patients ultimately gain access to more cures and treatments more quickly.”
 
“GPhA commends House Energy and Commerce Committee chairman Fred Upton, ranking member Frank Pallone [D-N.J.], Rep. Diana DeGette, Health Subcommittee chair Joe Pitts [R-Pa.], and Health Subcommittee ranking member Gene Green [D-Texas] for their bipartisan leadership around fostering the development of new cures while recognizing the balance between pharmaceutical competition and innovation,” stated Ralph Neas, president and CEO for the Generic Pharmaceutical Association. "GPhA and its members look forward to continuing to work with the Committee and stakeholders on the 21st Century Cures initiative to ensure and protect that balance."
 
“The thoughtful, year-long process that brought countless stakeholders to the table ultimately results in important steps forward for patients,” added John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America. “Exempting future Food and Drug Administration user fees from sequestration is critical to ensuring the FDA is able to fulfill its public health mission by fostering timely patient access to safe and effective new medicines and advancing regulatory science. We are pleased to see this important provision included in the legislation.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Boehringer Ingelheim’s Stiolto Respimat gets FDA approval

BY David Salazar

RIDGEFIELD, Conn. — The Food and Drug Administration has approved Boehringer Ingelheim's Stiolto Respimat (tiotropium bromide and olodaterol), a once-daily inhaler meant to treat obstructed airflow in patients, the company announced Tuesday. 
 
According to Danny McBryan, MD, Boehringer Ingelheim’s VP, clinical development and medical affairs, as a maintenance treatment initiated around the time of diagnosis, Stiolto Respimat has the potential to improve airflow quickly. 
 
“Patients may appreciate the benefits of a maintenance medication that improves lung function within five minutes, lasts all day and reduces the use of rescue inhalers,” McBryan said, adding that Stiolto Respimat had “proven to be more effective than either SPIRIVA or olodaterol alone, with a comparable safety profile.”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Fruth Pharmacy, FoodFair ink partnership

BY Antoinette Alexander

POINT PLEASANT, W. Va. — Fruth Pharmacy is setting up shop inside two FoodFair locations this summer, providing customers with a convenient way to pick up prescriptions while they shop.


In mid-June, Fruth Pharmacy will take over the existing pharmacy located inside Powell's Food Fair in Pomeroy, Ohio.  Later in mid-July, Fruth will open a new pharmacy in the Grayson, Ky., FoodFair. Opening the location in Grayson will expand the Fruth Pharmacy chain into a new state.


Although, the Fruth locations in FoodFair will be reduced in size, customers will still get to experience Fruth Pharmacy’s full service pharmacy.  Fruth Pharmacy offers prescription counseling, prescription savings card, prescription rewards club, immunizations, medication flavorings for children and more.  Customers will also be able to take advantage of the Fruth mobile app.  

The app can be downloaded from the Apple, Android, or Windows app stores for free. Once the app is installed and the customer has registered, prescription ordering is easy. Customers can request refills, keep track of medications, and receive text alerts when medications are ready for pick-up. The app also has a built-in feature to help keep track of family members’ medications, in the event a customer is a caregiver.


The FoodFair locations will increase the Fruth Pharmacy chain to 28 stores in Ohio, West Virginia and Kentucky.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?